Company overview
Basic information
Company name
LIETUVOS IMUNOLOGŲ DRAUGIJA
Company code
190735292
Registered address
Vilnius, Gedimino pr. 3, LT-01103
Registration date
1996-05-29
Company age: 30 y. 5 mo.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Email
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Website
https://www.imunologai.lt
Company manager
For registered members only
Log in
Indicators
Risk factors
Activity
Legal form
Association
NACE activity
Activities of professional membership organisations
Sector
Namų ūkiams paslaugas teikiančios ne pelno institucijos
Ownership form
Private without foreign capital
Beneficiary of support
Yes, since 2005-09-26
NVO
Non-governmental organization since 2025-01-09
LIETUVOS IMUNOLOGŲ DRAUGIJA
Company code: 190735292
Address: Vilnius, Gedimino pr. 3, LT-01103
Description
This description was generated by artificial intelligence.
LIETUVOS IMUNOLOGU DRAUGIJA is an operational association registered in 1996 and based in Vilnius, at Gedimino pr. 3, Vilniaus m. municipality, Vilniaus county. It is classified as a public entity in the non-profit institutions providing services to households sector and is described as privately owned, with governance structured as CEO only. Its activity is recorded under EVRK code T.94.12.00, Activities of professional membership organisations. The company is classified as micro-sized. Financially, the association reported revenue of EUR 60.3K in 2025, up from EUR 8.3K in 2024 and EUR 3.0K in 2023. Net profit in 2025 was EUR 15.4K, with a profit margin of 25.6%. Total assets increased to EUR 47.0K in 2025, while liabilities remained EUR 300. The reported revenue trend shows strong year-on-year growth in 2025 and a substantial increase over the two-year period.
Download a detailed company report
Make confident decisions with all the information about LIETUVOS IMUNOLOGŲ DRAUGIJA. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.